

Anti-Spike RBD (SARS-CoV-2/COVID-19) Human Neutralizing Antibody

CATALOG NUMBER: SCV2-RBD-h12, 100 µg

Introduction The novel coronavirus (SARS-CoV-2), previously called 2019-nCoV, is a newly identified

coronavirus causing the ongoing outbreak of atypical pneumonia in Wuhan China from late 2019.

The genome of SARS-CoV-2 has 89% nucleotide identity with bat SARS-like-CoVZXC21 and 82% with that of human SARS-CoV. The phylogenetic trees of their orf1a/b, Spike, Envelope, Membrane and Nucleoprotein also clustered closely with those of the bat, civet and human SARS coronaviruses. However, the external subdomain of Spike's receptor binding domain (RBD) of

SARS-CoV-2 shares only 40% amino acid identity with other SARS-related coronaviruses.

Applications Western blot (1:1,000-1:2,000) and ELISA (1:5,000-10,000), May be used for other applications

Description Human monoclonal anti-spike RBD (SARS-CoV-2/COVID-19) neutralizing antibody

Immunogen Recombinant SARS-CoV-2 spike S1 protein

Specificity Reacts to SARS-CoV-2 Spike RBD and S1 protein. Cross-reaction to RBD domain and S1 from

other coronavirus not tested.


Purification Affinity chromatography

Isotype Human IgG1

Storage Store at -20 °C; Stable for 6-months from the date of shipment when kept at 4 °C. Non-hazardous.

No MSDS required.

Concentration 1 μg/μl in PBS, pH7.4



96-well corning ELISA plate was coated with SARS-CoV-2 spike RBD protein (Cat# SCV2-RBD-050P) at a concentration of 1.5 µg/ml.